Intersect ENT - PDFSEARCH.IO - Document Search Engine

Intersect ENT
Results: 36

#	Item
31	Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery PROPEL™ mini Offers Same Clinical Benefits and Dose of Mometasone Add to Reading List Source URL: propelopens.com Language: English - Date: 2014-04-17 10:10:29 Headaches Rhinology Sinusitis Otolaryngology Mometasone furoate Sinus Clinical trial Medicine Health General practice
32	Media Contact: Nicole Osmer[removed]removed] Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif. Add to Reading List Source URL: propelopens.com Language: English - Date: 2014-04-17 10:11:54 General practice Headaches Sinusitis Otolaryngology Sinus Paranasal sinuses Medtronic Medicine Human anatomy Rhinology
33	Intersect ENT Announces Publication of Positive Data from Three Studies of Company’s Drug-Eluting Sinus Implants Results Published in International Forum of Allergy & Rhinology Add to Clinical Evidence Supporting Benef Add to Reading List Source URL: propelopens.com Language: English - Date: 2014-10-08 16:52:23 General practice Headaches Sinusitis Sinus Mometasone furoate Medicine Rhinology Otolaryngology
34	Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis Menlo Park, Calif. – Aug 11, 2014 – Intersect EN Add to Reading List Source URL: propelopens.com Language: English - Date: 2014-08-11 09:42:48 Headaches Sinusitis Otolaryngology Sinus Medicine Rhinology General practice
35	Intersect ENT Announces Pricing of its Initial Public Offering Menlo Park, Calif. – July 24, 2014 – Intersect ENT, Inc., a commercial drug-device company committed to improving the quality of life for patients with e Add to Reading List Source URL: propelopens.com Language: English - Date: 2014-07-24 07:55:15 Securities Finance United States Securities and Exchange Commission Corporate finance SEC filings Prospectus Registration statement Forward-looking statement Piper Jaffray Financial economics Stock market Investment
36	Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman Menlo Park, Calif. – June 4, 2014 – Intersect ENT, Inc., a commercial stage drug-device company committed to improving the quality of life Add to Reading List Source URL: propelopens.com Language: English - Date: 2014-06-04 20:41:13 Electronic Arts Biology Software development Video game development Geron Corporation Oncology

UPDATE